CRISPR Therapeutics AG CRSP

CRISPR Therapeutics AG is a biotechnology company with headquarters in Zug, Switzerland. Founded in 2013, the firm develops gene-based medicines to treat patients with serious diseases. Operating internationally, the company develops products in a wide range of fields, including hemoglobinopathies, immuno-oncology, regenerative medicine and in vivo approaches.

The company makes use of CRISPR/Cas9 gene-editing technology to modify, delete or correct specific regions of human DNA. Genes are edited by precisely cutting DNA and allowing natural DNA repair processes to complete the job. CRISPR Therapeutics AG's lead programme targets β-thalassemia and sickle cell disease. It entered clinical testing in August 2020. One of the company's projects involves treating type 1 diabetes by transplanting gene-edited pancreatic cells into the patient to enable patients to produce their own insulin.

Trading on the NASDAQ, CRISPR Therapeutics AG stock uses the ticker CRSP and has been listed since October 2016. CRISPR Therapeutics AG operates a number of subsidiaries, including Casebia Therapeutics, CRISPR Therapeutics, Inc. and CRISPR Therapeutics Limited. In May 2021, CRISPR announced a strategic partnership with Nkarta, Inc. to develop gene-edited cell therapies for cancer.

Track CRSP share price movements by adding it to your eToro watchlist now and diversify your virtual portfolio with this medical research company.